The γ-aminobutyric acid (GABA) ergic system is the primary inhibitory neurotransmission
system in the mammalian brain. Its dysregulation has been shown in multiple brain
conditions, but in Alzheimer's disease (AD) studies have provided contradictory results.
Here, we conducted a systematic review with meta-analysis to investigate whether the
GABAergic system is altered in AD patients compared to healthy controls (HC), following the
PRISMA 2020 Statement. We searched PubMed and Web of Science from database …

Background Cholinergic and glutamatergic dysfunctions have been widely described in
Alzheimer's disease (AD). However, the role of other neurotransmitter systems, such as the
GABAergic, remains poorly understood. In fact, studies evaluating GABAergic
neurotransmission in AD patients have provided contradictory results, pointing to a need for
a consensus in the literature regarding the GABAergic system in AD. Thus, we aimed at
examining whether the GABAergic system is altered in AD. Method We systematically …